Alemtuzumab to Treat Severe Aplastic Anemia

NCT00195624 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Severe Aplastic Anemia, Refractory
Severe Aplastic Anemia, Relapse

Interventions

BIOLOGICAL: Alemtuzumab (Campath )
DRUG: Cyclosporine

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)